Neeraj Agarwal
SMS Medical College · 1,477 works · 35,901 citations · h-index 84
Top works
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- Kidney Cancer
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
- Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
- Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
- Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
- Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
- The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study
- Bladder Cancer
- Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
- Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
- TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
- Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
- Kidney Cancer, Version 3.2015
- Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology